Loading...
XJPX
4591
Market cap25mUSD
Oct 09, Last price  
71.00JPY
1D
-1.39%
1Q
-4.05%
Jan 2017
-89.91%
IPO
-96.17%
Name

Ribomic Inc

Chart & performance

D1W1MN
XJPX:4591 chart
P/E
—
P/S
1,324.12
EPS
—
Div yield, %
—
Shrs. gr., 5y
14.06%
Rev. gr., 5y
-49.57%
Revenues
3m
+42.38%
229,065,000168,613,000151,220,000479,871,000121,911,00093,773,00064,727,0007,949,000121,385,00091,963,00080,909,00065,968,99902,107,0003,000,000
Net income
-1.15b
L+12.41%
-313,404,000-276,249,000-211,831,00010,298,000-323,313,000-646,603,000-753,048,000-836,624,000-855,042,000-1,187,194,000-1,684,754,000-1,653,002,000-1,024,237,000-1,018,939,000-1,145,360,000
CFO
-1.11b
L+11.42%
-153,240,000-162,525,000134,584,000-324,703,000-706,894,000-694,797,000-830,464,000-902,288,000-1,149,038,000-1,499,224,000-1,708,626,000-932,757,000-996,966,000-1,110,863,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Ribomic Inc. is a Japanese biopharmaceutical company dedicated to identifying and advancing medicinal compounds. The firm employs RNA aptamers in its drug development efforts, targeting various significant health issues such as wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma. Furthermore, Ribomic manufactures specialized separating agents used for the affinity purification of human IgG and Fc-fusion proteins. Established in 2003, the company's main operations are based in Tokyo, Japan.

Key people

Taro Nishikido
Executive Officer, Director of General Affairs and Human Resources, Manager of Internal Audit Office
Tatsuo Adachi
Executive Officer, Director of Exploratory Research
Kazumasa Akita
Executive Officer, Director of Business Development · since 2023
Ryoji Futagawa
Executive Officer, Director of Development Research
Satoshi Ishimaru
Executive Officer, Director of Intellectual Property Science · since 2023
Shomi Nakajima
Executive Officer, Director of Legal Affairs
Yoshihide Nakamura
Executive Officer, Chief Director of Research and Development, Director of Clinical Development · since 2023
Hisato Oiwa
Chief Financial Officer, Executive Officer, Chief Director of Administration, Director · since 2021
Nobuo Yanagi
Executive Officer, Director of Business Development · since 2023
Wataru Yonebayashi
Executive Officer, Director of Finance and Accounting
Shoji Yonebayashi
Executive Officer, Director of Accounting and Finance · since 2022
Kenro Ando
Executive Officer, Chief Director of Research and Development, Director · since 2025
Yoshikazu Nakamura
President, Chief Executive Officer, Representative Director · since 2020
Toshinobu Fujiwara
Independent Director · since 2023
Senya Matsufuji
Independent Director · since 2021
Toshiaki Nishihata
Independent Director · since 2016
URL
https://www.ribomic.com/
IPO date
Sep 25, 2014
Employees
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT